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Increased accumulation of adipose tissue macrophages in obesity propagates chronic inflammation that is
closely associated with insulin resistance and type 2 diabetes. Semaphorin 3E, a guidance molecule for
neurons, takes on a new role in obesity by directing the recruitment of macrophages in visceral adipose
tissue (Shimizu et al., 2013).Obesity, insulin resistance, and type 2
diabetes are increasing to epidemic pro-
portions and are major contributors to
morbidity andmortality worldwide. During
obesity visceral adipose tissue is infil-
trated by large numbers of immune cells,
particularly macrophages, which incite
metabolic dysregulation (Glass and Olef-
sky, 2012). The expanding adipose
undergoes extensive remodeling, and
this influx of macrophages likely helps to
maintain tissue homeostasis, at least
initially. However, these adipose tissue
macrophages (ATMs) secrete proinflam-
matory cytokines, most notably tumor
necrosis factor alpha (TNFa) and inter-
leukin-6 (IL-6), which fuel chronic inflam-
mation, contributing to the development
of systemic insulin resistance (Glass and
Olefsky, 2012). A new study by Shimizu
et al. (2013) identifies Semaphorin 3E,
typically thought of as a developmental
axon guiding cue, as a potent regulator
of adipose tissue macrophage accu-
mulation in obesity that contributes to
systemic insulin resistance.
Growing evidence supports the partici-
pation of neuronal guidance molecules in
the regulation of the immune system
where they exert diverse effects on leuko-
cyte migration, adhesion, and inflamma-
tory responses (Takamatsu and Kumano-
goh, 2012). The class 3 Semaphorins are
highly conserved, secreted, and matrix-
associated proteins that signal through
various transmembrane receptors in the
Plexin or Neuropilin family to mediate
both repulsive and attractive signaling
(Pu¨schel, 1999). Shimizu et al. observed
a selective increase in expression of one
member of this class, Sema3e, in visceraladipose tissue of mice fed a high-fat diet
and a parallel increase in serum Sema-
phorin 3E levels (Shimizu et al., 2013).
Notably, Sema3e expression localized to
adipocytes, whereas its receptor Plex-
inD1 was found on both adipocytes
and accumulating macrophages. In vitro,
Semaphorin 3E, acting via PlexinD1 and
Neuropilin 1, was a potent inducer of
macrophage migration and proinflamma-
tory cytokine expression (Figure 1). More-
over, Semaphorin 3E inhibited insulin
signaling in adipocytes by blocking Akt
phosphorylation. Together, these findings
suggested that secretion of Semaphorin
3E in expanding adipose promotes ATM
and adipocyte pathogenic functions that
contribute to insulin resistance. Indeed,
overexpression of Sema3e using an
adipocyte-specific promoter induced
ATM accumulation, insulin resistance,
and glucose intolerance in chow-fed
mice, whereas global deletion of Sema3e
improved diet-induced adipose inflam-
mation and metabolic dysfunction.
As observed in obese mice, individuals
with diabetes show increased plasma
levels of Semaphorin 3E indicating a po-
tential role for Semaphorin 3E-plexinD1
signaling in human metabolic disease
(Shimizu et al., 2013). In mice, delivery of
a soluble form of plexinD1 was sufficient
to counteract the effects of Semaphorin
3E in obesity, including ATM accumu-
lation, insulin resistance, and glucose
intolerance (Shimizu et al., 2013). Thus,
counteracting the systemic effects of
Semaphorin 3E may be sufficient to
mitigate provocation of insulin resistance,
at least in part by reducing the content
of proinflammatory ATMs. Shimizu et al.Cell Metabolism 1also show that Semaphorin 3E/plexinD1
signaling increases markers of classically
activated ‘‘M1’’ macrophages and p38
MAPK signaling, which promote proin-
flammatory responses. Increased acti-
vation of p38 has been observed in
omental adipose tissue of human obese
subjects (Bashan et al., 2007), and in
mice, treatment with p38 inhibitors sup-
pressed obesity and insulin resistance
triggered by consumption of a high-fat
diet (Maekawa et al., 2010).
To understand the mechanisms of
Semaphorin 3E upregulation, the authors
turned to the cancer field where Sema3
family members are known to be induced
by the tumor suppressor p53. p53 is
regulated by a variety of stress signals,
including the accumulation of reactive
oxygen species and DNA damage that
characterize expanding adipose tissue.
Indeed, HFD-fed mice with adipocyte-
selective deficiency of p53 showed
reduced expression of Sema3e and
Plxnd1, which correlated with a decrease
in macrophage infiltration and insulin
resistance (Shimizu et al., 2013). Con-
versely, administration of a p53 activator
to chow-fed mice was sufficient to
incite adipocyte Sema3e expression and
adipose tissue inflammation. This mecha-
nism may be relevant to the recent link of
adiposity to aging, which is associated
with increased p53-transcriptional activ-
ity; however, this awaits further studies.
Recent studies have demonstrated
roles for Semaphorin 3E in the patho-
genesis of other chronic inflammatory
diseases, including rheumatoid arthritis
(Mangasser-Stephan et al., 1997) and
atherosclerosis (Wanschel et al., 2013).8, October 1, 2013 ª2013 Elsevier Inc. 461
Figure 1. Semaphorin 3E Regulates Macrophage Accumulation in
Obese Adipose Tissue and Promotes Insulin Resistance
Expression of Semaphorin 3E (Sema3E) is induced in adipocytes by p53, and
its secretion promotes an influx of monocyte-derived macrophages (purple
cells) into the adipose tissue. These adipose tissue macrophages secrete
proinflammatory mediators such as tumor necrosis factor alpha (TNFa) and
interleukin (IL)-6, which contribute to insulin resistance. In addition, Sema3E
contributes directly to insulin resistance by blocking Akt phosphorylation
and signaling.
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expression profiles of macro-
phages in progressing or
regressing atherosclerotic
plaques identified Sema3e
as one of the genes most
highly downregulated during
the resolution of athero-
sclerotic inflammation (Feig
et al., 2012). Furthermore
Sema3e was upregulated in
macrophages by oxidized
low-density lipoprotein (LDL)
and hypoxia, and its expres-
sion was associated with
inflammatory M1 but not
the alternatively activated
M2 macrophages (Wanschel
et al., 2013). This is relevant
to adipose inflammation,
where there is a shift from
the reparative M2 macro-
phage phenotype in lean adi-
pose to a predominantly M1macrophage population, which secretes
the proinflammatory cytokines that pro-
mote insulin resistance. Interestingly,
Semaphorin 3E was explored as a macro-
phage retention molecule in the context
of atherosclerosis and was shown to
block the response of macrophages to
chemokines (CCL19, CCL21) that have
been implicated in the exodus of macro-
phages from plaques (Wanschel et al.,
2013). Whether Semaphorin 3E plays a
similar role in macrophage retention in
adipose tissue remains unknown. Future
studies of macrophage trafficking will be
needed to determine whether Sema-
phorin 3E promotes macrophage accu-
mulation in the obese adipose tissue by
inciting the recruitment of monocytes or
by providing a ‘‘stop’’ signal to retain cells
in this inflammatory site. Furthermore,
it will be of interest to determine how
Semaphorin 3E coordinates monocyte
and macrophage trafficking with other
chemotactic signals, particularly CCL2,462 Cell Metabolism 18, October 1, 2013 ª20which is known to play a role in the
recruitment of macrophages into adipose
tissue. Given the bifunctional nature of
Semaphorin 3E, one attractive hypothesis
is that it switches between exerting repul-
sive or attractive effects by engaging
different receptors or signaling pathways
in macrophages. Such a scenario would
allow for monocytes to be attracted to
the site of inflammation, and then upon
resolution, to be directed from the tissue.
An open question therefore is, might
soluble forms of plexinD1 be potential
therapeutic strategies in obesity? In this
context, it is important to ask, to what
extent does the Semaphorin 3E/plexinD1
signaling family contribute to different
inflammatory responses, in which a bal-
ance of proinflammatory and prorepair
signals by macrophages are essential
for clearance of pathogens and resolu-
tion of tissue inflammation? In the case
of Semaphorin 3A/plexinA4, this path-
way exacerbates the ‘‘cytokine storm’’13 Elsevier Inc.induced by Toll-like receptor
agonists in a murine model
of severe sepsis (Wen et al.,
2010). Although further
studies are required to dis-
cern the possible therapeutic
opportunities in obesity for
Semaphorin 3E /plexinD1, the
study by Shimizu et al. high-
lights the expanding func-
tions of such guidance cues,
whose actions were previ-
ously thought to be restricted
to thenervous system, in regu-
lating immune cell function
and inflammatory responses.REFERENCES
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